QLS4131 clinical trials
Also written QLS4131.
How each study uses QLS4131 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the QLS4131 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- QLS4131
- 4
Studies by the year they started
6 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 3
Qilu Pharmaceutical Co., Ltd. (3) · Institute of Hematology & Blood Diseases Hospital, China (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test QLS4131.
- Dec 2026A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus ErythematosusPhase 1 · Qilu Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses QLS4131 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131Not yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07933432Written as QLS4131
- QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary DiseaseNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07903636Written as QLS4131
- QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07903623Written as QLS4131
- BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)Not yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07751471Written as QLS4131
- A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus ErythematosusNot yet recruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT07001839Written as QLS4131 for Injection.
- A Study of QLS4131 in Patients With Recurrent or Refractory Multiple MyelomaNot yet recruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT06500507Written as QLS4131 Injection
Given beside what is tested · 1 — QLS4131 is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered3
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131Nov 12, 2026NCT07933432
- QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell LeukemiaOct 29, 2026NCT07903623
- QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary DiseaseOct 29, 2026NCT07903636